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Obesity is a known cause of metabolic syndrome which
includes Type II diabetes, hypertension, and dyslipidemia. It
is well documented that insulin resistance contributes to the
mortality and the incidence of metabolic syndromes including
central obesity, dyslipidemia, hyperglycemia and hypertension.
Both obesity and diabetes are emerging topics for researchers
to consider as having a possible causal association with cancer
since the two factors have been viewed as risk factors for
cancer. The present paper introduced the hypothesis of a
possible causal relationship between obesity, insulin resistance
and cancer and reviews relevant existing studies in this area.
More efforts and studies are needed to clarify the mechanisms
and the common risk factors which might be incorporated into
interventions to prevent cancer and cardiovascular diseases as
top causes of death.
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Over the past 12 years, the prevalence of obesity
has increased in Korea from 20.8% in 1992 to
39.2% in 2004 (Fig. 1). Current studies show that
obesity and diabetes, a closely related disease,
may be risk factors for cancer. It is important to
note that both cancer and cardiovascular diseases,
the leading causes of death in Korea, are closely
associated with obesity. Obesity is a known cause
of several metabolic diseases, including Type II
diabetes, hypertension, and dyslipidemia.
1 Insulin
resistance, which is considered a primary factor in
the mechanisms of metabolic syndromes, is also
known to raise the risk of cardiovascular disease.
2
Currently, both obesity and diabetes are being
investigated because these conditions have a pos-
sible causal association with cancer, as they have
been viewed as risk factors for the disease.
3,4
Common risk factors for chronic diseases such as
cardiovascular disease, diabetes, and cancer are:
smoking, obesity, and a sedentary lifestyle; how-
ever, these risk factors have different mechanisms
of action in each of the chronic diseases.
5 Previous
studies have hypothesized that risk factors such as
obesity, diabetes, insulin resistance, inflammation,
and oxidative stress might increase the risk of
cancer. However, the association between these
risk factors and cancer has not been clearly ex-
plained.
The causal relationship between the disease
mechanisms and risk factors is not yet fully
understood. Understanding the role of insulin
resistance in the cause of death in each of these
diseases may help to explain the relationship
between risk factors, pathogenesis, diseases, and
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Fig. 1. Prevalence of obesity in Korean men.
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cause of death (Fig. 2). The development of each
disease and metabolic syndrome, and the involve-
ment of risk factors in inflammation, insulin resis-
tance, and oxidative stress may interact. Re-
searchers speculate that cancer may share a simi-
lar disease and risk factor interaction mechanism
with that of cardiovascular disease. Fig. 2 explains
the hypothesis of how risk factors affect the
disease mechanism and result in a metabolic syn-
drome and ultimately end in the causes of death.
The model focuses not on a possible single
mechanism with single risk factor involvement,
but instead on the systematic processes of multi-
risk factor effects on the development of diseases.
Reducing the major causes of death and the
incidence of fatal illnesses are the main goals in
public health. One of the main prevention
strategies is to reduce the prevalence of obesity.
This paper introduces the hypothesis that a causal
relationship exists between obesity, insulin resis-
tance, and cancer, and also reviews previous
relevant studies.
Mechanisms of developing cancer and
insulin resistance
Inflammatory response and insulin resistance
Insulin is an anti-inflammatory hormone. Ma-
cronutrient intake can initiate pro-inflammatory
actions. Insulin is also known to be related with
pro-inflammatory transcription factors, such as
nuclear factor-kappa B (NF-κB), activating pro-
tein-1 (AP-1), matrix metalloproteinase-9 (MMP-
9), tissue factor (TF), and plasminogen activator
inhibitor-1 (PAI-1). If insulin resistance interrupts
the regular insulin activities of controlling inflam-
mation and pro-inflammatory transcription fac-
tors, then correlated genes may be activated that
can enhance the inflammatory process.
Recent studies revealed the role of insulin on
anti-inflammation in two perspectives. First, in-
sulin reduced the level of CRP (C reactive protein)
and monocyte chemotactic protein-1 (MCP-1) in
Type II diabetics who were given the insulin
treatment for two weeks. It was observed that
insulin also reduced inflammatory markers in
patients with severe hyperglycemia. In addition,
insulin lowered the concentration level of inflam-
matory markers in mice injected with an endo-
toxin that caused inflammation. The inflamma-
tory markers that are controlled by insulin are
IL-1β, IL-6, macrophage migration inhibition fac-
tor (MIF), and tumor necrosis factor-alpha (TNF-
) α.
6
Adipocytes and macrophages share a common
role in inflammatory signaling and metabolic
responses. Research has shown that TNF- , IL-6, α
adiponectin, resistin, and leptin are associated
Fig. 2. Increased cancer risk through
insulin resistance: a multi-dimensional
model.Obesity, Insulin Resistance and Cancer Risk
Yonsei Med J Vol. 46, No. 4, 2005
with various inflammatory and obesity mecha-
nisms. TNF-α and IL-6 were increased among
obese subjects. Adiponectin, which is usually de-
creased in obese people, improves insulin sensi-
tivity and plays a role in anti-inflammatory ac-
tions. Resistin, sometimes induced by inflamma-
tion, can raise insulin resistance.
A cell has to maintain a balance between meta-
bolism and inflammation; however, in over-nu-
trition or an obesity state, insulin resistance can
occur due to the ineffective process of nutritional
metabolism. In metabolic overload states, like
glucose metabolism, obesity, and over-nutrition,
there are increases in reactive oxygen species
(ROS) in the mitochondria, protein production,
and also in ER (endoplasmic reticulum) stress.
These situations eventually initiate inflammation
by activating inflammatory-signaling pathways.
These types of stimuli activate several serine/
threonine kinases, and in turn interrupt insulin- sig-
naling pathways. In the inflammatory signal trans-
mission process, the primary process is thought to
be a reduced function of the insulin receptors. In-
flammatory responses interrupt insulin-signaling
pathways and activate insulin resistance.
Occurrence of oxidative stress and insulin
resistance
Oxidative stress interferes with glucose meta-
bolism and insulin secretion in pancreatic beta
cells.
7,8 In addition, this stress is known to be a
part of the pathogenesis of hypertension and ath-
erosclerosis.
9,10 Recent studies have reported that
oxidative stress is higher not only in diabetics, but
also in subjects with increased adipose accumula-
tion. The whole-body oxidative stress is known to
be related to body mass index (BMI).
11
According to Furukawa et al.,
12 accumulated
adipose tissue increases whole-body oxidative
stress in human subjects as well as in mice. In ani-
mal experiments, obese mice had increased ROS
only in their adipose tissues. The increased ROS
is also accompanied by an increase in the
appearance of nicotinamide adenine dinuclotide
phosphate (NADPH) oxidase and a decrease in
anti-oxidative enzymes. In an adipocyte culture
experiment, increases in fatty acids resulted in
oxidative stress increases, and also a reduction in
adiponectin. Fatty acids also raised the levels of
PAI-1, IL-6, and MCP-1. In another study with
obese mice, an inhibitor for NADPH oxidase
reduced the production of ROS in adipose tissue
and controlled adipocytokine, as well as diabetes,
high cholesterol, and fatty liver. In summary,
increased oxidative stress in adipose tissue is an
initial step of pathogenesis which can develop
into a metabolic syndrome. Thus, this might be
one of the targets for the prevention of such
metabolic syndromes.
Cancer and insulin resistance
There are several hypotheses that explain the
mechanism of carcinogenesis in obesity through
inflammation, oxidative stress, and insulin resis-
tance. It has been suggested that these mecha-
nisms include increased cell proliferation due to
hyperinsulinemia, cell growth from growth hor-
mones, and reduced apoptosis.
Insulin resistance is an interrupted state in the
biological response to insulin. It is reported that
chronic hyperinsulinemia is associated with vari-






16 The mechanism of the carcino-
genesis of insulin is thought to be associated with
both insulin receptors and with endogenous hor-
mone metabolism. Specifically, insulin promotes
the production and activity of insulin-like growth
factor 1 (IGF1), which can promote cell prolifera-
tion in an over-nutrition state. In one study,
researchers found that insulin and IGF1 promoted
cell proliferation and inhibited cell apoptosis.
17 In
an experimental animal study, cancer growth was
reduced when an IGF1 receptor was removed or
when the IGF1 concentration was reduced.
18
Hyperinsulinemia can affect the production of sex
hormones such as androgen and estrogen, which
may be associated with cancer growth.
Although IGF1 is not relatively increased as
BMI increases, researchers assume that free IGF1
can result in cell proliferation.
3 Eighty percent of
IGF1 is combined with insulin-like growth factor
binding protein (IGFBP3), which is known to in-
terfere with cancer cell growth. Epidemiological
experiments and studies report that an increase in
IGFBP3 may prevent breast, colorectal, prostate,Sun Ha Jee, et al.
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and lung cancers. In obese subjects, IGFBP3 levels
remained constant or showed a slight increase.
While the IGF1 level is occasionally reduced, it is
thought that the increase of IGFBP3 in obesity is
due to the negative feedback caused by increases
in free IGF1.
3,18
More studies are needed on the factors that may
influence cancer, including growth factors, insu-
lin-like growth factor binding proteins, and sex
hormones. The role of insulin warrants further
research since obesity and metabolic syndromes
are on the rise. Comprehensive interventions on
lifestyle change are also needed.
An epidemiological study on cancer risk and
metabolic syndromes
It is well documented that insulin resistance
contributes to the mortality and incidence of
metabolic syndromes including central obesity,
dyslipidemia, hyperglycemia, and hypertension.
Increased cancer risk among diabetics
Diabetes is one of the major health concerns in
Western countries. It is estimated that approxi-
mately 7% of adults and 15% of the elderly
population have diabetes.
19 It has been 100 years
since diabetes and cancer were first shown to have
a possible association.
20 However, studies asso-
ciating specific types of cancer with diabetes are
inconsistent. For example, some studies indicate
that diabetes might increase the risk of endome-
trial cancer
21 and female colorectal cancer. Other
studies suggest that diabetes may not be related
with any cancers except for pancreatic cancer and
non-Hodgkin's lymphoma.
22,23
In a prospective study that included 1.3 million
Koreans, Jee et al.
24 reported that higher fasting
blood sugar levels (140 mg/dL and above) in-
creased the risk of all types of cancer by up to 1.29
times. (Male: HR=1.29; 95% confidence interval
[CI], 1.22-1.37, Female: HR=1.23; 1.09-1.39). Speci-
fically, they found that fasting blood sugar levels
were highly associated with an increased risk of
pancreatic cancer (Male: HR=1.91; 1.52-2.41, Fe-
male: HR=2.05; 1.43-2.93). Among men, a higher
fasting sugar level was strongly associated with a
higher risk of cancer of the esophagus, liver, and
colon/rectum, while women had a higher risk of
liver and cervical cancer (Fig. 3). The findings on
Fig. 3. Hazard ratios of diabetes versus non-diabetes on
various cancers in Korean men and women. Source: Jee et
al. JAMA 2005;293:194-202.
Fig. 4. Hazard ratios for all cancer
deaths by fasting serum glucose levels
in Korean men according to body mass
index, 1993-2002. Source: Jee et al.
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the fasting blood sugar levels and cancer risk
were the same for the groups with low and high
BMIs (Fig. 4).
In the United States, 65% of the population is
overweight and/or obese. Worldwide, obesity is a
major public health issue because of its association
with diabetes. Findings that associate high fasting
blood sugar levels and cancer risk are significant
in Korea where there is not a high prevalence of
obesity.
25
Breast cancer, the most common cancer among
women, is affected by many risk factors such as
age, obesity, hormones, a past history of benign
breast tumors, family history, and genetics.
26 Six-
teen percent of breast cancer patients over 65
years old are diabetic.
27 The risk factors for Type
II diabetes such as age and obesity are also known
to be risk factors for breast cancer. Three mecha-
nisms were suggested that connect diabetes and
breast cancer: insulin pathway activation, insulin-
like growth factor activation, and endogenous sex
hormones. Based on the results of cohort research
and case-control research, it was concluded that
Type II diabetes may contribute to 10 to 20% of
breast cancer risk. Gestational diabetes is also
thought to increase the risk of breast cancer. Type
I diabetes did not show an association with cancer
risk. Diabetes and its complications can interfere
with cancer treatment and diagnosis, which in
turn may negatively affect the treatment results of
breast cancer patients.
23
Colorectal cancer may be also associated with
diabetes. Several large-scale prospective studies
provided evidence that diabetes is associated with
colorectal cancer. Five studies on the association
between colorectal cancer and diabetes showed
inconsistent results, with different types and
ranges of association. The wide range of results
between these studies was associated with gender
differences. In an 18 year Prospective Nurses'
Health Study, Hu et al.
21 reported that there are
strong associations between colorectal cancer and
diabetes among women. The relative ratio for
colorectal cancer was 1.43 (95% CI, 1.10-1.87; p=
0.009) and was 2.39 (95% CI, 1.46-3.92; p=0.0005)
for fatal colorectal cancer. This study revealed that
the relative risk of fatal colorectal cancer declined
in patients with long-term diabetes. This trend
was thought to be due to relatively low insulin
levels in the bloodstream caused by a longer
period of living in a diabetic state. This supports
the hypothesis that hyperinsulinemia in the blood
may contribute to the risk of colorectal cancer as
a reactive result of insulin resistance.
In a cancer prevention study sponsored by the
American Cancer Society, Will et al.
28 compared
diabetic patients with non-diabetic patients to
determine which group had a higher risk of
colorectal cancer over a period of 13 years. The
study examined factors such as BMI, family his-
tory, physical activity level, race, smoking, diet,
alcohol consumption, and aspirin intake. The
findings indicated that the risk of colorectal cancer
was higher for male diabetic patients (RR=1.30;
1.03-1.65) but not significantly higher for female
diabetic patients (RR=1.16; 0.87-1.53). Nilsen et
al.
29 followed their subjects for 12 years to deter-
mine whether an association existed between
colorectal cancer risk factors (i.e. diabetes, blood
sugar level, physical activity, or BMI) and the risk
of colorectal cancer. After adjusting for age, the
risk of colorectal cancer was higher for females
(RR=1.55; 1.04-2.31) and was not significantly
higher for males with a history of Type II dia-
betes. In a study by Kono et al.,
30 821 cases of sig-
moid colorectal adenomas were compared with a
4,372-person control group. Family histories were
studied and the subjects underwent a 75g oral
glucose tolerance test. The subjects were then
categorized into a normal group, an impaired
glucose tolerance group, a newly-diagnosed non-
insulin-dependent diabetes group, and a treat-
ment-in-progress diabetes group. This study
found that there was an association between sig-
moid colorectal adenomas and non insulin-de-
pendent diabetes. A large-scale case controlled
study in Italy compared 1,225 colorectal cancer
patients and 4,154 in-patients without cancer.
31
The odds ratio for colorectal cancer was slightly
higher among diabetic patients over 40 years old
(OR=1.4; 1.1-1.7). A stronger association was
found among patients who had been living with
diabetes for more than 10 years and also had
colorectal cancer that was first diagnosed at the
age of 60 and older (OR=1.6; 1.1-2.3). This study
also reported that BMI, physical activity, alcohol
intake, energy, and fiber intake did not affect the
association. These research results support theSun Ha Jee, et al.
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hypothesis that diabetes and high insulin levels
might be triggering factors for colorectal cancer.
4
Increase in cancer among hypertensives
After controlling for age, smoking, physical
activity, BMI, alcohol consumption, diabetes, and
cholesterol levels in the blood, a cohort study with
450,000 Korean men showed that hypertension
was not an independent risk factor for lung can-
cer, but it did increase the mortality rate among
lung cancer patients who were smokers (RR=1.8,
95% CI; 1.0-3.1).
32 In another cohort study in-
volving 570,000 Koreans, hypertension was found
to be an independent risk factor for kidney can-
cer.
33
Higher risk for cancer among patients with a
high cholesterol level
A total of 7,619 Japanese-Americans were fol-
lowed for 30 years in a cohort study. The
researchers found that a high BMI increased the
risk of colon cancer but was not associated with
rectal cancer. In addition, triglyceride levels in the
blood did not increase the risk of colorectal
cancer.
34
In a study of 103 breast cancer patients com-
pared with 103 members of a control group, the
breast cancer patients had higher leptin and
triglyceride levels and lower blood high density
lipoproteins (HDL).
35
However, it is still not clear how diseases and
their conditions contribute to the risk of cancer, or
how the interaction of these collective diseases,
along with metabolic syndromes, contribute to
cancer. Further studies are needed as follows.
Suggestions for future studies
According to recent studies on the effects of
insulin, most of the results suggested that insulin
resistance played a basic role in the development
of cancer, although insulin resistance may not be
the only factor involved in metabolic syndromes.
36
Hyperinsulinemia, impaired glucose tolerance,
Type II diabetes, high triglyceride levels in the
blood, and a lowered HDL can be explained in
terms of the insulin-resistant effects on the meta-
bolic mechanisms of carbohydrates and fat. In
addition, insulin and metabolic syndromes may
contribute to the risks associated with coronary
heart disease and cerebrovascular disease.
6
A metabolic syndrome can be described as a
complex of risk factors for cancer including obe-
sity, insulin resistance, inflammation, and diseases
such as diabetes and atherosclerosis. Additional
studies are needed to further investigate the
relationship between metabolic syndromes and
the mechanism of cancer development. These
studies may provide evidence that preventive
interventions for metabolic syndromes can reduce
the risk of cardiovascular diseases and reduce the
risk of cancer. Additional studies are needed to
elucidate disease mechanisms and common risk
factors in order to develop effective interventions
to prevent the current top causes of death: cancer
and cardiovascular diseases.
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